We hypothesize that the individual adiponectin-enhancing properties of pitavastatin and L-glutamine, coupled with their combinatorial AdipoR1 expression-enhancing property resulted in the significant correction of T2D manifestations. Here, ADIPOQ is linked to type 2 diabetes mellitus.